Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted serine protease of the proprotein convertase family, expressed mainly in hepatocytes and also in intestine and kidney.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted serine protease of the proprotein convertase family, expressed mainly in hepatocytes and also in intestine and kidney. Its role in lipid metabolism is unusual in that it does not act by cleaving its target: after autocatalytic processing it is secreted with its prodomain still bound, blocking the catalytic site, and it regulates the low-density lipoprotein receptor (LDLR) purely by binding it. Normally LDLR delivers LDL to the endosome, releases it, and returns to the surface to work again. PCSK9 bound to the receptor prevents that release, so the whole complex is routed to the lysosome and degraded. Fewer receptors means less hepatic LDL uptake and higher circulating LDL cholesterol (LDL-C). Human genetics settled the direction of effect: gain-of-function mutations cause autosomal dominant hypercholesterolemia, while loss-of-function variants confer lifelong low LDL-C and markedly reduced cardiovascular risk in people who are otherwise healthy — which is why PCSK9 became one of the most confidently validated targets in preventive cardiology before any drug existed.
Because statins raise PCSK9 through the same SREBP-2 program by which they upregulate LDLR, blocking the protease is strongly synergistic with them and removes part of the ceiling on statin monotherapy. Inhibition is achieved clinically through monoclonal antibodies that intercept circulating PCSK9 and through small interfering RNA (siRNA) that silences its hepatic synthesis and is dosed twice yearly, with macrocyclic peptides and CRISPR-based gene editing approaches remaining experimental. Outcome trials have confirmed that the LDL-C reduction translates into fewer cardiovascular events, and no adverse consequence of very low LDL-C has emerged, consistent with what the loss-of-function carriers predicted.
Beyond cholesterol homeostasis, PCSK9 acts on other receptors and has been implicated in vascular biology, immune modulation and oncology, including ferroptosis, antigen presentation and tumor immune evasion — placing it, alongside its established role in cardiovascular disease, at the intersection of several therapeutic domains.
Where the papers sit
13 papers from the last 6 months study Proprotein convertase subtilisin/kexin type 9 (PCSK9) directly · updated from PubMed 12 Oct 2026
Study type 3 clinical trials · 3 observational · 1 human data · 3 preclinical · 3 unclassified
Themes 3 themes · 1 new direction
-
Cardiovascular PCSK9 Treatment
PCSK9 inhibition is moving from LDL cholesterol reduction toward durable prevention of major adverse cardiovascular events in established coronary and atherosclerotic disease. Evolocumab data support efficacy in Japanese patients and those without prior ischemic events, while inclisiran trials test sustained control after acute coronary syndrome and event reduction. Real-world registry data warn that discontinuation may erode cardiovascular protection. Oral laroprovstat broadens the field, but comparative event evidence for newer agents remains incomplete.
6 papers · 46.2%
-
Engineered PCSK9 Therapies
PCSK9 therapy is moving toward durable LDL-receptor control through engineered biologics, liver-targeted nucleic-acid delivery, and gene editing. Recyclable antibody shields aim to preserve receptor homeostasis without immune complexes, while enlicitide illustrates macrocyclic peptide engineering. Polyamine-oleic acid and piperazine-derived lipid nanoparticles support mRNA delivery, and vascular smooth muscle-cell targeting links PCSK9 suppression to reduced ferroptosis and abdominal aortic aneurysm progression. Translation, tissue specificity, and long-term safety remain open.
5 papers · 38.5%
-
Lipid-Lowering Safety Outcomes
Statins and PCSK9 inhibitors are being assessed beyond LDL cholesterol for metabolic and neurologic safety. Observational and Mendelian-randomization analyses examine statin exposure in neuropathic pain, while comparative data suggest PCSK9 inhibitors may carry less type 2 diabetes risk than other lipid-lowering agents. The evidence is nonrandomized and addresses different outcomes, limiting direct comparison. The shared question is whether lipid lowering changes diabetes and pain risk.
2 papers · 15.4%
PCSK9 is a vascular smooth-muscle ferroptosis driver in abdominal aortic aneurysm
The human abdominal aortic aneurysm lesions, PPE- or Ang II-induced murine aneurysm models, and primary vascular smooth-muscle cells studied by the AAA paper place PCSK9 in a role beyond the set’s usual LDL-C-lowering, delivery, or immune-regulatory applications. Rather than merely serving as a therapeutic target for altering circulating lipids, PCSK9 overexpression in vascular smooth-muscle cells aggravated aneurysm pathology and induced iron accumulation and lipid peroxidation by triggering ferritinophagy, whereas PCSK9 knockdown reduced Ang II-induced ferroptosis. This assigns PCSK9 a cell-autonomous role as a driver of vascular smooth-muscle injury and AAA progression, making PCSK9 degradation a potential disease-modifying strategy for AAA 42269711Jun.
Papers
The 13 papers from the last 6 months that study Proprotein convertase subtilisin/kexin type 9 (PCSK9) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Cardiovascular PCSK9 Treatment (6)
- Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes - Real-World Evidence From the Kyoto PCSK9 Registry. Circulation journal : official journal of the Japanese Circulation Society · 12 Jul 2026 PMID 42438016
- Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. American heart journal · 27 May 2026 PMID 42203164
- Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. Circulation · 15 May 2026 PMID 42137960
- Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. Journal of the American Heart Association · 14 May 2026 PMID 42132192
- PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study. European heart journal · 16 Apr 2026 PMID 41989103
- Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients. Journal of atherosclerosis and thrombosis · 16 Apr 2026 PMID 41987365
Engineered PCSK9 Therapies (5)
- A recyclable antibody shield preserves LDL receptor homeostasis and enables durable lipid control without immune complex formation. Pharmacological research · 6 Aug 2026 PMID 42562083
- Endogenous-metabolite-inspired polyamine-oleic acid lipids for safe mRNA delivery and PCSK9 gene editing. Journal of controlled release : official journal of the Controlled Release Society · 4 Jul 2026 PMID 42401241
- Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression. Cell proliferation · 10 Jun 2026 PMID 42269711
- Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR. Journal of medicinal chemistry · 27 May 2026 PMID 42201324
- Piperazine-Derived Diamine Lipid Nanoparticles Targeting to the Liver for Delivering Clustered Regularly Interspaced Short Palindromic Repeat Editing of PCSK9 to Durably Maintain Plasmatic Low-Density Lipoprotein Cholesterol in Low Levels. ACS applied bio materials · 4 May 2026 PMID 42080223
Lipid-Lowering Safety Outcomes (2)
- Lower Risk of Type 2 Diabetes Mellitus With PCSK9 Inhibitors Compared With Other Lipid-Lowering Agents Among Patients With Hyperlipidaemia. Diabetes/metabolism research and reviews · 11 Jun 2026 PMID 42274293
- Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses. Molecular neurobiology · 4 May 2026 PMID 42081017
By study type
Clinical trials (3)
- Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. American heart journal · 27 May 2026 PMID 42203164
- Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. Circulation · 15 May 2026 PMID 42137960
- Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. Journal of the American Heart Association · 14 May 2026 PMID 42132192
Observational studies and case reports (3)
- Lower Risk of Type 2 Diabetes Mellitus With PCSK9 Inhibitors Compared With Other Lipid-Lowering Agents Among Patients With Hyperlipidaemia. Diabetes/metabolism research and reviews · 11 Jun 2026 PMID 42274293
- Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses. Molecular neurobiology · 4 May 2026 PMID 42081017
- PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study. European heart journal · 16 Apr 2026 PMID 41989103
Human data, design not indexed (1)
- Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients. Journal of atherosclerosis and thrombosis · 16 Apr 2026 PMID 41987365
Preclinical: animal, cell and lab studies (3)
- A recyclable antibody shield preserves LDL receptor homeostasis and enables durable lipid control without immune complex formation. Pharmacological research · 6 Aug 2026 PMID 42562083
- Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR. Journal of medicinal chemistry · 27 May 2026 PMID 42201324
- Piperazine-Derived Diamine Lipid Nanoparticles Targeting to the Liver for Delivering Clustered Regularly Interspaced Short Palindromic Repeat Editing of PCSK9 to Durably Maintain Plasmatic Low-Density Lipoprotein Cholesterol in Low Levels. ACS applied bio materials · 4 May 2026 PMID 42080223
Unclassified: not yet indexed with MeSH (3)
- Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes - Real-World Evidence From the Kyoto PCSK9 Registry. Circulation journal : official journal of the Japanese Circulation Society · 12 Jul 2026 PMID 42438016
- Endogenous-metabolite-inspired polyamine-oleic acid lipids for safe mRNA delivery and PCSK9 gene editing. Journal of controlled release : official journal of the Controlled Release Society · 4 Jul 2026 PMID 42401241
- Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression. Cell proliferation · 10 Jun 2026 PMID 42269711
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-08-26 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.